News
UCLA Considers Underserved Populations When Licensing Medical Research Discoveries
UCLA Considers Underserved Populations When Licensing Medical Research Discoveries
UCLA is committed to its public-service mission of transparent and equitable biomedical research that enhances understanding of disease and leads to new treatments. Discoveries made in UCLA’s laboratories are available as medications worldwide.
We Are Hiring: Life Sciences Business Development Officer
.jpg)
Please see our listing here
Nanotech Energy named CES 2022 Innovation Award Winner
Erasca Announces FDA Clearance of UCLA Developed Drug
UCLA Researchers David Nathanson, Ph.D., Michael Jung, Ph.D., and Timothy Cloughesy, M.D. developed ERAS-801, an orally available small molecule epidermal growth factor receptor (EGFR) inhibitor specifically designed to have high central nervous system (CNS) penetration for the treatment of recurrent glioblastoma multiforme (rGBM). The company Erasca licensed ERAS-801 from Katmai Pharmaceuticals, Inc. and received FDA clearance.
UCLA TDG Innovation Magazine Dec 2021
Inside this edition
-Annual Report numbers
-Extrico Health
-Amazon Hub
and more
10th Annual UCLA MedTech Partnering Conference
Registration is open! Join us at The 10th Annual MedTech Partnering Conference
Tuesday, March 8, 2022
at UCLA Luskin Conference Center
Streaming is also an option
Giving Tuesday Support UCLA Innovation Fund
The UCLA Innovation Fund
UCLA created the Innovation Fund to bridge the gap between early-stage research and translation of life-impacting technology. Click on the button to learn more.
UCLA and Amazon join forces to create Science Hub for Humanity and Artificial Intelligence
UCLA
At a kickoff event on the anniversary of the birth of the internet, speakers included Pietro Perona and Prem Natarajan of Amazon, and Leonard Kleinrock, Jayathi Murthy, Andrea Ghez, Jens Palsberg and Stefano Soatto of UCLA.
Christine Wei-li Lee | October 29, 2021
